Literature DB >> 27886033

Efficacy of lytic Staphylococcus aureus bacteriophage against multidrug-resistant Staphylococcus aureus in mice.

Joseph Michael Ochieng' Oduor1, Nyamongo Onkoba, Fredrick Maloba, Washingtone Ouma Arodi, Atunga Nyachieo.   

Abstract

INTRODUCTION: The use of bacteriophages as an alternative treatment method against multidrug-resistant bacteria has not been explored in Kenya. This study sought to determine the efficacy of environmentally obtained lytic bacteriophage against multidrug-resistant Staphylococcus aureus (MDRSA) bacterium in mice.
METHODOLOGY: Staphylococcus aureus bacterium and S. aureus-specific lytic phage were isolated from sewage and wastewater collected within Nairobi County, Kenya. Thirty mice were randomly assigned into three groups: MDRSA infection group (n = 20), phage-infection group (n = 5), and non-infection group (n = 5). The MDRSA infection group was further subdivided into three groups: clindamycin treatment (8 mg/kg; n = 5), lytic phage treatment (108 PFU/mL (n = 5), and a combination treatment of clindamycin and lytic phage (n = 5). Treatments were done at either 24 or 72 hours post-infection (p.i), and data on efficacy, bacterial load, and animal physical health were collected.
RESULTS: Treatment with phage was more effective (100%) than with clindamycin (62.25% at 24 hours p.i and 87.5% at 72 hours p.i.) or combination treatment (75% at 24 hours p.i. and 90% at 72 hours p.i.) (p < 0.001).
CONCLUSIONS: The results show that the environmentally obtained S. aureus lytic bacteriophage has therapeutic potential against MDRSA bacterium in mice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27886033     DOI: 10.3855/jidc.7931

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  5 in total

Review 1.  Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials.

Authors:  Lucile Plumet; Nour Ahmad-Mansour; Catherine Dunyach-Remy; Karima Kissa; Albert Sotto; Jean-Philippe Lavigne; Denis Costechareyre; Virginie Molle
Journal:  Front Cell Infect Microbiol       Date:  2022-06-17       Impact factor: 6.073

2.  Means to Facilitate the Overcoming of Gastric Juice Barrier by a Therapeutic Staphylococcal Bacteriophage A5/80.

Authors:  Ryszard Międzybrodzki; Marlena Kłak; Ewa Jończyk-Matysiak; Barbara Bubak; Anna Wójcik; Marta Kaszowska; Beata Weber-Dąbrowska; Małgorzata Łobocka; Andrzej Górski
Journal:  Front Microbiol       Date:  2017-03-23       Impact factor: 5.640

Review 3.  Animal Models of Phage Therapy.

Authors:  Samuel Penziner; Robert T Schooley; David T Pride
Journal:  Front Microbiol       Date:  2021-01-28       Impact factor: 5.640

Review 4.  Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far.

Authors:  Marzanna Łusiak-Szelachowska; Ryszard Międzybrodzki; Zuzanna Drulis-Kawa; Kathryn Cater; Petar Knežević; Cyprian Winogradow; Karolina Amaro; Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska; Justyna Rękas; Andrzej Górski
Journal:  J Biomed Sci       Date:  2022-03-30       Impact factor: 8.410

5.  Phage Therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant Acinetobacter baumannii in Mice.

Authors:  Yunfen Hua; Tingting Luo; Yiqi Yang; Dong Dong; Rui Wang; Yanjun Wang; Mengsha Xu; Xiaokui Guo; Fupin Hu; Ping He
Journal:  Front Microbiol       Date:  2018-01-09       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.